

## Part VI: Summary of the risk management plan

### Summary of risk management plan for <Product name> (Imatinib)

This is a summary of the risk management plan (RMP) for <Product name>. The RMP details important risks of <Product name>, how these risks can be minimised, and how more information will be obtained about <Product name>'s risks and uncertainties (missing information).

<Product name>'s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how <Product name> should be used.

#### I. The medicine and what it is used for

<Product name> is indicated for the treatment of

- paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment
- paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis
- adult patients with Ph+ CML in blast crisis
- adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy
- adult patients with relapsed or refractory Ph+ ALL as monotherapy
- adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements
- adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR $\alpha$  rearrangement.

<Product name> is indicated for

- the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
- the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment
- the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery (see SmPC for the full indication). It contains Imatinib as the active substance and it is given orally.

#### II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of <Product name>, together with measures to minimise such risks and the proposed studies for learning more about <Product name>'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

If important information that may affect the safe use of <Product name> is not yet available, it is listed under 'missing information' below.

### **II.A List of important risks and missing information**

Important risks of <Product name> are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of <Product name>. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>Summary of safety concerns</b>	
Important identified risks	<ul style="list-style-type: none"> <li>• None</li> </ul>
Important potential risks	<ul style="list-style-type: none"> <li>• Second primary malignancy</li> <li>• Tolerability during pregnancy and pregnancy outcomes</li> </ul>
Missing information	<ul style="list-style-type: none"> <li>• Paediatric patients: long term follow up Paediatric patients below 2 years of age</li> </ul>

### **II.B Summary of important risks**

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### **II.C Post-authorisation development plan**

#### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of <Product name>.

#### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for <Product name>.